Detalhe da pesquisa
1.
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Curr Treat Options Oncol
; 19(1): 6, 2018 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29368125
2.
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
BMC Urol
; 17(1): 1, 2017 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28056941
3.
Telehealth Is a Sustainable Population Health Strategy to Lower Costs and Increase Quality of Health Care in Rural Utah.
JCO Oncol Pract
; 16(7): e557-e562, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32463765
4.
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Urol Oncol
; 37(6): 352.e19-352.e24, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770300
5.
Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC).
Mol Cancer Ther
; 18(3): 726-729, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587554
6.
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
PLoS One
; 14(1): e0210415, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30682039
7.
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 16(4): 288-292, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674118
8.
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Am Soc Clin Oncol Educ Book
; 37: 319-329, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28561652
9.
Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
Urol Oncol
; 35(12): 676-677, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054496
10.
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Immunotherapy
; 9(8): 681-692, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653573
11.
PD-1 checkpoint inhibition: Toxicities and management.
Urol Oncol
; 35(12): 701-707, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889921
12.
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.
Front Oncol
; 7: 56, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28421161
13.
Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
Oncotarget
; 8(20): 33614-33620, 2017 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28431395
14.
Streptococcus Intermedius: A Mimicker of Brain Metastases and A Potential Pitfall for Radiation Oncologists.
Adv Radiat Oncol
; 6(4): 100689, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34409201
15.
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Clin Genitourin Cancer
; 14(2): 153-9, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26781820
16.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
Ecancermedicalscience
; 10: 676, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27729941
17.
Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
Immunotherapy
; 9(6): 463-466, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472906
18.
Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.
JAMA Oncol
; 3(6): 856-857, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28208175